γ-aminobutyric acid B2 receptor: A potential therapeutic target for cholangiocarcinoma in patients with diabetes mellitus.

Titleγ-aminobutyric acid B2 receptor: A potential therapeutic target for cholangiocarcinoma in patients with diabetes mellitus.
Publication TypeJournal Article
Year of Publication2023
AuthorsSaengboonmee, C, Sorin, S, Sangkhamanon, S, Chomphoo, S, Indramanee, S, Seubwai, W, Thithuan, K, Chiu, C-F, Okada, S, Gingras, M-C, Wongkham, S
JournalWorld J Gastroenterol
Volume29
Issue28
Pagination4416-4432
Date Published2023 Jul 28
ISSN2219-2840
KeywordsBaclofen, beta Catenin, Bile Duct Neoplasms, Bile Ducts, Intrahepatic, Cell Line, Tumor, Cell Proliferation, Cholangiocarcinoma, Diabetes Mellitus, Glucose, Glycogen Synthase Kinase 3, Humans, Hyperglycemia
Abstract

BACKGROUND: The association between diabetes mellitus (DM) and the increased risk and progression of cholangiocarcinoma (CCA) has been reported with unclear underlying mechanisms. Previous studies showed that γ-aminobutyric acid (GABA) B2 receptor (GABBR2) was upregulated in CCA cells cultured in high glucose (HG) conditions. Roles of GABA receptors in CCA progression have also been studied, but their association with DM and hyperglycemia in CCA remains unclarified.

AIM: To investigate the effects of hyperglycemia on GABBR2 expression and the potential use of GABBR2 as a CCA therapeutic target.

METHODS: CCA cells, KKU-055 and KKU-213A, were cultured in Dulbecco Modified Eagle's Medium supplemented with 5.6 mmol/L (normal glucose, NG) or 25 mmol/L (HG) glucose and assigned as NG and HG cells, respectively. GABBR2 expression in NG and HG cells was investigated using real-time quantitative polymerase chain reaction and western blot. Expression and localization of GABBR2 in CCA cells were determined using immunocytofluorescence. GABBR2 expression in tumor tissues from CCA patients with and without DM was studied using immunohistochemistry, and the correlations of GABBR2 with the clinicopathological characteristics of patients were analyzed using univariate analysis. Effects of baclofen, a GABA-B receptor agonist, on CCA cell proliferation and clonogenicity were tested using the MTT and clonogenic assays. Phospho-kinases arrays were used to screen the affected signaling pathways after baclofen treatment, and the candidate signaling molecules were validated using the public transcriptomic data and western blot.

RESULTS: GABBR2 expression in CCA cells was induced by HG in a dose- and time-dependent manner. CCA tissues from patients with DM and hyperglycemia also showed a significantly higher GABBR2 expression compared with tumor tissues from those with euglycemia (

CONCLUSION: GABBR2 is upregulated by HG and holds a promising role as a therapeutic target for CCA regardless of the glucose condition.

DOI10.3748/wjg.v29.i28.4416
Alternate JournalWorld J Gastroenterol
PubMed ID37576707
PubMed Central IDPMC10415970

Similar Publications